Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 146,025 | $2,511,630 | -27% | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.80 | 200 | $2,760.00 | 926,352 | 2026-05-19 | Filing | |
| $13.98 | 10,000 | $139,822.00 | 926,152 | 2026-05-19 | Filing | |
| $13.98 | 6,009 | $83,981.18 | 916,152 | 2026-05-18 | Filing | |
| $13.95 | 200 | $2,790.00 | 910,143 | 2026-05-15 | Filing | |
| $13.80 | 100 | $1,380.00 | 909,943 | 2026-05-15 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.04 | 599 | $9,607.96 | 15,551 | 2026-10-27 | Filing | |
| $5.06 | 789 | $3,992.34 | 4,115 | 2026-02-23 | Filing | |
| $8.20 | 100,000 | $820,000.00 | 2,378,969 | 2023-03-07 | Filing | |
| $8.20 | 100,000 | $820,000.00 | 2,378,969 | 2023-03-07 | Filing | |
| $12.50 | 50,329 | $629,112.50 | 1,251,755 | 2022-06-03 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 794,720 | $13,669,184 | 0% | |
| 2. | 33,943 | $583,942 | 0% | |
| 3. | 19,458 | $334,692 | 0% | |
| 4. | 812 | $13,967 | 0% | |
| 5. | 421 | $7,241 | 0% |